Production (Stage)
Maze Therapeutics, Inc.
MAZE
$12.93
-$0.41-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 27.44% | 7.19% | 19.10% | 3.75% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 26.37% | 28.96% | 5.95% | 11.45% | |
| Operating Income | -26.37% | -28.96% | 3.96% | -11.45% | |
| Income Before Tax | -0.90% | -12.33% | -1.15% | -32.38% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -0.90% | -11.30% | -0.02% | -32.38% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -0.90% | -11.30% | -0.02% | -32.38% | |
| EBIT | -26.37% | -28.96% | 3.96% | -11.45% | |
| EBITDA | -28.28% | -31.47% | 3.23% | -12.39% | |
| EPS Basic | 91.77% | 82.43% | 90.66% | -28.20% | |
| Normalized Basic EPS | 90.35% | -18.03% | 13.88% | -9.42% | |
| EPS Diluted | 91.77% | 79.89% | 90.66% | -28.20% | |
| Normalized Diluted EPS | 90.35% | -18.03% | 13.88% | -9.42% | |
| Average Basic Shares Outstanding | 1,125.22% | 5.07% | 5.03% | 3.26% | |
| Average Diluted Shares Outstanding | 1,125.22% | 5.07% | 5.03% | 3.26% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |